Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Notable Labs Announced Initial Safety And Efficacy Data Of Fosciclopirox And The Performance Of PPMP From The Phase 2a Trial In Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia, R/R AML

Author: Benzinga Newsdesk | December 18, 2023 09:08am

- PPMP Accurately Predicted Patient Outcomes in Fosciclopirox Phase 2a Leukemia Trial -

- Predictive Results Further Advance PPMP and Corroborate Outcomes from 4 PPMP Validation Trials -

- Furthers Opportunity to Accelerate PPMP Use in Front-End Drug Development -

Posted In: NTBL